Author: Benzinga Newsdesk | August 08, 2025 05:43am
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(7.01) per share which missed the analyst consensus estimate of $(1.49) by 372.05 percent. This is a 97.15 percent increase over losses of $(246.24) per share from the same period last year.